Marie-Laure Risse Selected Research

isatuximab

10/2022	Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis.
6/2022	Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.
5/2022	Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.
1/2022	Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis.
1/2022	Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma.
1/2021	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
1/2021	PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma.
1/2020	Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design.
5/2018	Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marie-Laure Risse Research Topics

Disease

9	Multiple Myeloma 10/2022 - 05/2018
2	Neoplasms (Cancer) 01/2021 - 10/2003
1	Residual Neoplasm 01/2022
1	Urinary Bladder Neoplasms (Bladder Cancer) 01/2013
1	Stomach Neoplasms (Stomach Cancer) 11/2006

Drug/Important Bio-Agent (IBA)

9	isatuximabIBA 10/2022 - 05/2018
8	Dexamethasone (Maxidex)FDA LinkGeneric 10/2022 - 05/2018
7	carfilzomibIBA 10/2022 - 01/2020
3	Monoclonal AntibodiesIBA 06/2022 - 01/2021
2	pomalidomideIBA 01/2021 - 05/2018
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2021
2	Cisplatin (Platino)FDA LinkGeneric 01/2013 - 11/2006
1	antineoplaston A10 (A 10)IBA 01/2022
1	Gemcitabine FDA Link 01/2013
1	larotaxelIBA 01/2013
1	Pharmaceutical PreparationsIBA 11/2006
1	Docetaxel (Taxotere)FDA Link 11/2006
1	thiamine triphosphorate (TTP)IBA 11/2006
1	Fluorouracil (Carac)FDA LinkGeneric 11/2006
1	Irinotecan (Camptosar)FDA LinkGeneric 10/2003

Therapy/Procedure

5	Therapeutics 01/2022 - 11/2006
1	Intravenous Infusions 10/2003